Clinical trials for Lung cancer
323 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Lung cancer
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Localized
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Chemotherapy
Radiotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Radiotherapy
1 recruiting site
AstraZeneca
Early Access
Lung cancer
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Janssen
Early Access
Lung cancer
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Janssen
Early Access
Lung cancer
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Amgen
Phase 3
Lung cancer
#NCT07185997
#2025-522151-26-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
Bispecific T-cell engager antibodies
7 recruiting sites
ArriVent BioPharma, Inc
Phase 3
Lung cancer
#NCT07128199
#2025-521775-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Localized
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Chemotherapy
Excluded previous treatments at localized stage
Immunotherapy
18 recruiting sites
Taiho Oncology
Phase 3
Lung cancer
#NCT07431827
#2024-517337-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Localized
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Immunotherapy
Chemotherapy
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06345729
#2023-507776-42-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06931717
#2024-519901-36-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Localized
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
1 recruiting site
ETOP IBCSG Partners Foundation
Phase 3
Lung cancer
#NCT06758401
#2024-517968-36-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
14 recruiting sites
Pfizer